THERIVA BIOLOGICS INC Stock Price, News & Analysis

Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.

Theriva Biologics, Inc. (NYSE American: TOVX) is a clinical-stage company whose news flow centers on the development of therapeutics for cancer and related diseases. The company regularly issues updates on its lead oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec), including clinical trial results, regulatory interactions, and presentations at major medical congresses.

Investors following TOVX news can expect coverage of data from the VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, where Theriva has reported improved overall survival, progression free survival, and duration of response for patients treated with VCN-01 plus gemcitabine/nab-paclitaxel compared with standard-of-care alone. News also highlights regulatory milestones such as scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the design of a proposed Phase 3 trial, and company plans to discuss pivotal trial protocols with regulators.

Theriva’s releases also describe progress in retinoblastoma, including Phase 1 safety and clinical outcome data for intravitreal VCN-01 in refractory pediatric patients, as well as preclinical developments from the VCN-X discovery program, such as VCN-12. Beyond oncology, news items cover SYN-004 (ribaxamase) data in allogeneic hematopoietic cell transplant recipients and its potential role in protecting the gut microbiome and reducing acute graft-versus-host disease.

Additional TOVX news includes quarterly operational and financial updates, public offerings and warrant transactions, at-the-market equity programs, and proxy-related matters tied to share issuance approvals. This page aggregates these disclosures so readers can review Theriva’s clinical, regulatory, and financing developments in one place and track how its pipeline and capital strategy evolve over time.